Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 40-44

  Richardson, Thomas D ^a   Wojno, Kirk J ^a   Liang, Leonard W ^a   Giacherio, Donald A ^a   England, Barry G ^a   Henricks, Walter H ^a   Schork, Anthony ^a   Oesterling, Joseph E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURGERY; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY;

ADENOCARCINOMA; ADULT; AGED; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0030480329     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00608-5     Document Type: Article

References (24)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
3. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate specific antigen. J Urol 143: 1146-1152 (discussion 1152-1154), 1990.
4. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
5. Oesterling JE, Chute CG, Jacobsen SJ, Guess HA, Panser LA, Johnson CL, and Lieber MM: Longitudinal changes in serum PSA (PSA velocity) in a community based cohort of men. J Urol 149: 412A, 1993.
6. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WJ: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
7. Seaman E, Whang IS, Olsson CA, Katz A, Cooner WH, and Benson MC: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20: 653-663, 1993.
8. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
9. Collins GN, Lee RJ, McKelvie GB, Rogers AC, and Hehir M: Relationship between prostate specific antigen, prostate volume, and age in the benign prostate. Br J Urol 71: 445-450, 1993.
10. Anderson JR, Strickland D, Corbin D, Byrnes JA, and Zweiback E: Age specific reference ranges for serum prostate-specific antigen. Urology 46: 54-57, 1995.
11. el-Galley RES, Petros JA, Sanders W. H, Keane TE, Galloway N.T.M, Cooner WH, and Graham SD Jr: Normal range prostate-specific versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 46: 200-205,1995.
12. Stamey TA, Yang N, Hay AR, McNeal JE, Frieha F, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
13. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB, and Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139: 766-772, 1988.
14. McCormack RT, Rittenhouse HG, Finlay JO, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, and Oesterling JE: Molecular forms of prostate-specific antigen (PSA) and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
15. Christensson A, Laurell C-B, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
16. 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
17. 1-antichymotrypsin is the major form of prostate-specific antigen in the serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
18. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
19. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
20. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, and Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
21. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, and Lilja H: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentration and ratios. J Urol 154: 1090-1095, 1995.
22. van Stralen JP, Bossens MMF, de Reijke TM, and Sanders GTB: Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 32: 53-55, 1994.
23. Bjork T, Abrahamsson P-A, and Lilja H: Rates of clearance of free and complexed forms of PSA in serum after radical prostatectomy and transurethral microwave therapy. J Urol 153: 295A, abstract 265, 1995.
24. 1-antichymotiypsin. Urol Clin North Am 20: 681-686, 1993.